Increasing primary antibiotic resistance and ethnic differences in eradication rates of Helicobacter pylori infection in New Zealand-a new look at an old enemy

New Zealand Medical Journal

Volumn 126, Issue 1384, 2013, Pages

  Hsiang, John ^a   Selvaratnam, Sri ^a   Taylor, Susan ^a   Yeoh, Joey ^a   Tan, Yu Mwee ^a   Huang, Judy ^a   Patrick, Alasdair ^a  

^a MIDDLEMORE HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; METRONIDAZOLE; MOXIFLOXACIN; OMEPRAZOLE; PENICILLIN DERIVATIVE; TETRACYCLINE; ANTIINFECTIVE AGENT; PROTON PUMP INHIBITOR;

ABDOMINAL DISCOMFORT; ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; DIARRHEA; DISEASE ERADICATION; DIZZINESS; DRUG HYPERSENSITIVITY; ERADICATION THERAPY; ETHNIC DIFFERENCE; FEMALE; FOLLOW UP; GASTROSCOPY; HELICOBACTER INFECTION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METALLIC TASTE; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NEW ZEALAND; PREVALENCE; PROSPECTIVE STUDY; STOMACH BIOPSY; THERAPY EFFECT; UNSPECIFIED SIDE EFFECT; ABORIGINE; ASIAN; CAUCASIAN; COHORT ANALYSIS; DRUG EFFECT; ETHNOLOGY; HELICOBACTER PYLORI; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; NEGRO; PHYSIOLOGY; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; BLACK PERSON; DRUG EFFECTS; HELICOBACTER INFECTIONS; OCEANIC ANCESTRY GROUP;

ADOLESCENT; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; COHORT STUDIES; DISEASE ERADICATION; DRUG RESISTANCE, BACTERIAL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GASTROSCOPY; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; NEW ZEALAND; OCEANIC ANCESTRY GROUP; OMEPRAZOLE; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84885811554     PISSN: 00288446     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Li Z, Zou D, Ma X, Chen J, Shi X, Gong Y, et al. Epidemiology of peptic ulcer disease: endoscopic results of the systematic investigation of gastrointestinal disease in China. Am J Gastroenterol 2010;105(12):2570-7.
2. Emilia G, Luppi M, Zucchini P, Morselli M, Potenza L, Forghieri F, et al. Helicobacter pylori infection and chronic immune thrombocytopenic purpura: long-term results of bacterium eradication and association with bacterium virulence profiles. Blood 2007;110(12):3833-41.
3. Huang JQ, Sridhar S, Chen Y, Hunt RH. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 1998;114(6):1169-79.
4. Megraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004;53(9):1374-84.
5. Fraser AG, Moore L, Hackett M, Hollis B. Helicobacter pylori treatment and antibiotic susceptibility: results of a five-year audit. Australian and New Zealand journal of medicine 1999;29(4):512-6.
6. Xia HH, Kalantar J, Talley NJ. Metronidazole-and clarithromycin-resistant Helicobacter pylori in dyspeptic patients in western Sydney as determined by testing multiple isolates from different gastric sites. Journal of gastroenterology and hepatology 1998;13(10):1044-9.
7. Liu W, Lu B, Xiao S. [Clarithromycin combined short-term triple therapies for eradication of Helicobacter pylori infection]. Zhonghua nei ke za zhi [Chinese journal of internal medicine] 1996;35(12):803-6.
8. Perez Aldana L, Kato M, Nakagawa S, Kawarasaki M, Nagasako T, Mizushima T, et al. The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance. Helicobacter 2002;7(5):306-9.
9. Hung KH, Sheu BS, Chang WL, Wu HM, Liu CC, Wu JJ. Prevalence of primary fluoroquinolone resistance among clinical isolates of Helicobacter pylori at a University Hospital in Southern Taiwan. Helicobacter 2009;14(1):61-5.
10. Glocker E, Stueger HP, Kist M. Quinolone resistance in Helicobacter pylori isolates in Germany. Antimicrobial agents and chemotherapy 2007;51(1):346-9.
11. Bogaerts P, Berhin C, Nizet H, Glupczynski Y. Prevalence and mechanisms of resistance to fluoroquinolones in Helicobacter pylori strains from patients living in Belgium. Helicobacter 2006;11(5):441-5.
12. Yamade M, Sugimoto M, Uotani T, Nishino M, Kodaira C, Furuta T. Resistance of Helicobacter pylori to quinolones and clarithromycin assessed by genetic testing in Japan. Journal of gastroenterology and hepatology 2011;26(9):1457-61.
13. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, et al. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut 2012;61(5):646-64.
14. Fock KM, Katelaris P, Sugano K, Ang TL, Hunt R, Talley NJ, et al. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. Journal of gastroenterology and hepatology 2009;24(10):1587-600.
15. De Francesco V, Giorgio F, Hassan C, Manes G, Vannella L, Panella C, et al. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis 2010;19(4):409-14.
16. EUCAST Clinical Breakpoints: European Committee on Antimicrobial Susceptibility Testing, 2012. http://www.eucast.org/clinical_breakpoints/
17. NZ Guidelines Group. Management of Dyspepsia and Heartburn. Wellington: New Zealand Guidelines Group, 2004.
18. Romano M, Iovene MR, Russo MI, Rocco A, Salerno R, Cozzolino D, et al. Failure of firstline eradication treatment significantly increases prevalence of antimicrobial-resistant Helicobacter pylori clinical isolates. J Clin Pathol 2008;61(10):1112-5.
19. Wu CY, Kuo KN, Wu MS, Chen YJ, Wang CB, Lin JT. Early Helicobacter pylori eradication decreases risk of gastric cancer in patients with peptic ulcer disease. Gastroenterology 2009;137(5):1641-8 e1-2.
20. Thompson AG. Regional differences in incidence of gastric and colonic cancer in the Maori of New Zealand. Postgrad Med J 2002;78(921):419-21.
21. Biggar M, Srinivasa S, Wickramarachchi B, Babor R, Poole GH, Hill AG. Gastric cancer location and histological subtype in Pacific people and Maori defies international trends. The N Z Med J 2011;124(1331):39-44.
22. Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013;62(1):34-42.
23. Ahmed D, Brooks H, McConnell M, Barbezat G. Antibiotic resistance in Helicobacter pylori: is it a problem in New Zealand? The New Zealand medical journal 2004;117(1200):U1022.
24. Sokwala A, Shah MV, Devani S, Yonga G. Helicobacter pylori eradication: A randomized comparative trial of 7-day versus 14-day triple therapy. S Afr Med J 2012;102(6 Pt 2):368-71.
25. Kim BG, Lee DH, Ye BD, Lee KH, Kim BW, Kim SG, et al. Comparison of 7-day and 14-day proton pump inhibitor-containing triple therapy for Helicobacter pylori eradication: neither treatment duration provides acceptable eradication rate in Korea. Helicobacter 2007;12(1):31-5.
26. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increa sing antibiotic resistance. Gut 2010;59(8):1143-53.
27. Gisbert JP, Calvet X, O'Connor A, Megraud F, O'Morain CA. Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol 2010;44(5):313-25.
28. Georgopoulos S, Papastergiou V, Xirouchakis E, Laudi F, Papantoniou N, Lisgos P, et al. Evaluation of a four-drug, three-antibiotic, nonbismuth-containing "concomitant" therapy as first-line Helicobacter pylori eradication regimen in Greece. Helicobacter 2012;17(1):49-53.
29. Hsu PI, Wu DC, Wu JY, Graham DY. Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter 2011;16(2):139-45.
30. Borody TJ, George LL, Brandl S, Andrews P, Lenne J, Moore-Jones D, et al. Helicobacter pylori eradication with doxycycline-metronidazole-bismuth subcitrate triple therapy. Scand J Gastroenterol 1992;27(4):281-4.
31. Dore MP, Leandro G, Realdi G, Sepulveda AR, Graham DY. Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach. Dig Dis Sci 2000;45(1):68-76.
32. Filipec Kanizaj T, Katicic M, Skurla B, Ticak M, Plecko V, Kalenic S. Helicobacter pylori eradication therapy success regarding different treatment period based on clarithromycin or metronidazole triple-therapy regimens. Helicobacter 2009;14(1):29-35.